Key clinical point: Statin use alongside imatinib therapy significantly improved deep molecular response (DMR) and major molecular response (MMR) in patients with chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Imatinib-treated patients receiving statins had higher rates of DMR (55.8% vs. 41.0%; P = .0016) and MMR (56.8% vs. 47.0%; P = .0048) at 5 years than those not receiving statins. Concomitant statin use was independently associated with DMR (hazard ratio [HR] 1.785; P = .001) and MMR (HR 1.541; P = .043).
Study details: Findings are from a retrospective analysis of 408 patients with CML-CP receiving imatinib therapy with (n = 88) or without (n = 320) statins.
Disclosures: This study was supported by a National Research Foundation of Korea grant funded by the Korean government. The authors declared no conflict of interests.
Source: Jang HJ et al. Cancers. 2021;13(21):5543 (Nov 4). Doi: 10.3390/cancers13215543.